The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
Peripheral T-cell lymphomas (PTCLs) have aggressive clinical behavior. Mayo Clinic researchers have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clinically useful end point in diffuse large B-cell lymphoma. Here, researchers assess EFS24 and subsequent overall survival in large, multinational PTCL cohorts. Based on the results, EFS24 stratifies subsequent outcome in PTCL. Patients with PTCL with primary refractory disease or early relapse have extremely poor survival. However, more than one-third of patients with PTCL remain in remission 2 years after diagnosis with encouraging subsequent overall survival, especially in younger patients. These marked differences in outcome suggest that EFS24 has utility for patient counseling, study design, and risk stratification in PTCL. The review was published in the Journal of Clinical Oncology.